Losartan in esrd

by GL Bakris 2024 Cited by 616creatinine, ESRD, or death in the losartan group compared with placebo. This risk reduction is similar to that seen for the entire losartan cohort in the study.

Losartan significantly reduced the risk for the combined endpoint of end-stage renal disease (ESRD), MI, stroke, or death by 21% (p 0.005), irrespective of whether all-cause or cardiovascular death was included in the analysis. In addition, losartan reduced the risk for the composite of ESRD or cardiovascular death by 19.2% (p 0.05).

For the primary end-point, losartan treatment reduced the composite of a doubling of the baseline serum creatinine concentration, ESRD, or death

losartan on renal and cardiovascular outcomes in patients with end-stage renal disease (ESRD), or death. The secondary outcome was

Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the within-trial incidence of ESRD but is projected to result in lifetime reductions in ESRD, increased survival, and overall cost savings to public institutions in Mexico.

Losartan reduced the incidence of doubling of serum creatinine, end-stage renal disease (ESRD), or death by 16% (P = 0.022) and reduced the risk of progression to ESRD, defined as the initiation of dialysis or transplantation, by 29% (P = 0.002). We set out to estimate the potential effect of losartan on the burden and costs associated with

For the primary end-point, losartan treatment reduced the composite of a doubling of the baseline serum creatinine concentration, ESRD, or death

CONCLUSIONSTreatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the incidence of ESRD, but also resulted

by A Arredondo 2024 Cited by 11Results. The projected lifetime incidence of ESRD for losartan patients was lower (66%) compared with placebo patients (83%). This reduction in ESRD resulted in